Keros Therapeutics
KROS
151 hedge funds and large institutions have $206M invested in Keros Therapeutics in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 55 reducing their positions, and 40 closing their positions.
28.42% more ownership
Funds ownership: 65.89% → 94.31% (+28%)
9% less funds holding
Funds holding: 166 → 151 (-15)
13% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 55
33% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 40
50% less capital invested
Capital invested by funds: $409M → $206M (-$203M)
55% less call options, than puts
Call options by funds: $1.37M | Put options by funds: $3.05M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$15.4M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.07M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.49M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$3.07M |
| 5 |
EF
Empowered Funds
Havertown,
Pennsylvania
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$11.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.94M |
| 3 |
Goldman Sachs
New York
|
-$5.65M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$5.17M |
| 5 |
AG
Algert Global
San Francisco,
California
|
-$3.94M |
KROS Hedge Fund Activity: Q1 2026 in Review
151 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2026, worth a combined $206M — down 50% from $409M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of KROS and 27 opened new positions — a net loss of 13 holders — while 55 trimmed existing stakes and 48 added.
The largest buyer was Nantahala Capital Management, adding an estimated $15.4M. The largest seller was Arrowstreet Capital, cutting an estimated $11.5M.
- 151 institutional investors held Keros Therapeutics (KROS) as of Q1 2026, down from 166 in Q4 2025.
- Funds reported $206M of Keros Therapeutics stock for Q1 2026, down 50% quarter-over-quarter.
- 27 funds opened new Keros Therapeutics positions in Q1 2026 and 40 closed out, a net change of -13 holders.
- The largest Keros Therapeutics buyer in Q1 2026 was Nantahala Capital Management, an estimated $15.4M added.
- The largest Keros Therapeutics seller in Q1 2026 was Arrowstreet Capital, an estimated $11.5M sold.
Based on aggregated 13F filings for Q1 2026.